[go: up one dir, main page]

MX2019001850A - Formulaciones para administracion oral de principios activos. - Google Patents

Formulaciones para administracion oral de principios activos.

Info

Publication number
MX2019001850A
MX2019001850A MX2019001850A MX2019001850A MX2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A MX 2019001850 A MX2019001850 A MX 2019001850A
Authority
MX
Mexico
Prior art keywords
oral administration
formulations
active principle
active agents
therapeutically active
Prior art date
Application number
MX2019001850A
Other languages
English (en)
Inventor
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Original Assignee
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd filed Critical Entera Bio Ltd
Publication of MX2019001850A publication Critical patent/MX2019001850A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden un principio terapéuticamente activo y un potenciador de la absorción tal como NAC, NAD, 5- CNAC, 4-MOAC, 4-CNAB o una sal de los mismos, para su uso en el tratamiento de una dolencia que se puede tratar mediante dicho principio terapéuticamente activo. Las composiciones son para la administración oral concomitante de dos o más de las formas de dosificación unitaria, que forman conjuntamente una cantidad terapéuticamente eficaz del principio terapéuticamente activo y una cantidad terapéuticamente eficaz del potenciador de la absorción. También se proporcionan composiciones multidosis que comprenden las dos o más de la forma de dosificación unitaria.
MX2019001850A 2016-08-17 2017-08-17 Formulaciones para administracion oral de principios activos. MX2019001850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375989P 2016-08-17 2016-08-17
PCT/IL2017/050920 WO2018033927A1 (en) 2016-08-17 2017-08-17 Formulations for oral administration of active agents

Publications (1)

Publication Number Publication Date
MX2019001850A true MX2019001850A (es) 2019-05-15

Family

ID=61196521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001850A MX2019001850A (es) 2016-08-17 2017-08-17 Formulaciones para administracion oral de principios activos.

Country Status (14)

Country Link
US (2) US12239691B2 (es)
EP (1) EP3500291A4 (es)
JP (4) JP7530173B2 (es)
KR (4) KR102832566B1 (es)
CN (4) CN116831978A (es)
AU (2) AU2017311698B2 (es)
BR (1) BR112019003136A2 (es)
CA (1) CA3033259A1 (es)
IL (3) IL321113A (es)
MX (1) MX2019001850A (es)
NZ (1) NZ751668A (es)
SG (1) SG11201901070YA (es)
WO (1) WO2018033927A1 (es)
ZA (1) ZA201901370B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975710C (en) * 2015-02-09 2023-08-08 Entera Bio Ltd. Treatment of osteoporosis
BR112019003136A2 (pt) 2016-08-17 2019-05-21 Entera Bio Ltd forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
AR117118A1 (es) * 2018-11-19 2021-07-14 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
CN118873509A (zh) * 2020-03-18 2024-11-01 西藏海思科制药有限公司 口服药物组合物
AU2023226092A1 (en) * 2022-02-24 2024-10-03 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
EP4482507A1 (en) * 2022-02-24 2025-01-01 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of active agents
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6984728B2 (en) 1993-09-24 2006-01-10 Schering Corporation Recombinant infectious laryngotracheitis virus and uses thereof
CN1162917A (zh) 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CN1228708A (zh) 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
MXPA01008611A (es) 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
KR100788970B1 (ko) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
NZ531018A (en) 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
MXPA04004567A (es) 2001-11-13 2004-09-10 Emisphere Tech Inc Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
WO2003051339A1 (fr) * 2001-12-19 2003-06-26 Sanwa Kagaku Kenkyusho Co.,Ltd Produit façonne du type a liberation controlee
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
CN1816324A (zh) 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
MX2007005991A (es) * 2004-11-19 2007-07-20 Smithkline Beecham Corp Producto farmaceutico.
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP5175553B2 (ja) 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
AU2006288703B2 (en) 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
BRPI0618723A2 (pt) 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado
US20070178155A1 (en) 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
MX2008012678A (es) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8703821B2 (en) 2006-04-18 2014-04-22 Emisphere Technologies Inc. Dialkyl ether delivery agents
CN101686948B (zh) * 2007-04-04 2013-06-19 希格默伊德药业有限公司 环孢菌素药物组合物
US20100303901A1 (en) 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
WO2009036084A2 (en) 2007-09-11 2009-03-19 Orahealth Corporation Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
CA2734442C (en) * 2008-08-18 2016-08-16 Oramed Ltd Methods and compositions for oral administration of proteins
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US20130138221A1 (en) 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2747563A4 (en) 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US9803731B2 (en) 2014-04-24 2017-10-31 American Axle & Manufacturing, Inc. Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location
EP2975118B1 (en) 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
CA2975710C (en) 2015-02-09 2023-08-08 Entera Bio Ltd. Treatment of osteoporosis
BR112019003136A2 (pt) 2016-08-17 2019-05-21 Entera Bio Ltd forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
JP2024054222A (ja) 2024-04-16
SG11201901070YA (en) 2019-03-28
IL312218B2 (en) 2025-11-01
EP3500291A4 (en) 2020-03-11
ZA201901370B (en) 2025-07-30
BR112019003136A2 (pt) 2019-05-21
AU2024211004A1 (en) 2024-09-05
AU2017311698B2 (en) 2024-09-05
IL312218B1 (en) 2025-07-01
JP2025114692A (ja) 2025-08-05
NZ751668A (en) 2022-07-29
KR20240093678A (ko) 2024-06-24
US20190209657A1 (en) 2019-07-11
CN116831978A (zh) 2023-10-03
KR20190039768A (ko) 2019-04-15
CN116850132A (zh) 2023-10-10
IL264880B2 (en) 2024-09-01
IL264880A (en) 2019-04-30
KR20240134254A (ko) 2024-09-06
US20240415936A1 (en) 2024-12-19
KR102832565B1 (ko) 2025-07-09
EP3500291A1 (en) 2019-06-26
IL321113A (en) 2025-07-01
JP7546622B2 (ja) 2024-09-06
CN116831977A (zh) 2023-10-03
IL312218A (en) 2024-06-01
IL264880B1 (en) 2024-05-01
JP7530173B2 (ja) 2024-08-07
JP7736834B2 (ja) 2025-09-09
CA3033259A1 (en) 2018-02-22
US12239691B2 (en) 2025-03-04
CN109862906A (zh) 2019-06-07
JP2019524836A (ja) 2019-09-05
KR102832566B1 (ko) 2025-07-09
KR20230088854A (ko) 2023-06-20
AU2017311698A1 (en) 2019-04-04
WO2018033927A1 (en) 2018-02-22
JP2022126766A (ja) 2022-08-30

Similar Documents

Publication Publication Date Title
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.